Intraventricular colistin sulphate as a last resort therapy in a patient with multidrug‐resistant Acinetobacter baumannii induced post‐neurosurgical ventriculitis

• Published in: British journal of clinical pharmacology 2022-07, Vol.88 (7), p.3490-3494
• Main Authors: Yu, Xu‐Ben, Huang, Yue‐Yue, Zhang, Xiao‐Shan, Wang, Yu‐Zhen, Shi, Da‐Wei, Zhang, Chun‐Hong, Chen, Jie, Wang, Xiao‐Rong, Lin, Guan‐Yang
• Format: Article
• Language: English
• Subjects: Acinetobacter baumannii; Acinetobacter Infections - drug therapy; Aged; Anti-Bacterial Agents; Cerebral Ventriculitis - drug therapy; Cerebral Ventriculitis - etiology; Colistin - pharmacology; Colistin - therapeutic use; colistin sulphate; Drug Resistance, Multiple, Bacterial; Humans; intraventricular; Male; Meningitis - drug therapy; Meningitis - etiology; ventriculitis
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.15238

Limited therapeutic options exist for multidrug‐resistant/extensively drug‐resistant Acinetobacter baumannii (MDR/XDR‐Ab) meningitis/ventriculitis. A combination of intravenous and intraventricular (IVT)/intrathecal (IT) polymyxins achieves good therapeutic outcomes for cases of healthcare‐associated MDR/XDR‐Ab meningitis/ventriculitis. Colistin is commercially available as colistin sulphate and its sulphomethylated derivative. However, the effect and safety of colistin sulphate in the treatment of MDR/XDR‐Ab meningitis/ventriculitis has not been reported. We report on a 66‐year‐old male patient who developed post‐neurosurgical ventriculitis caused by MDR‐Ab. IVT concomitant intravenous colistin sulphate was used as a last‐resort antimicrobial therapy, the patient's ventriculitis was dramatically improved, and the concentrations of CSF colistin were higher than the MIC breakpoint throughout the treatment. Meanwhile, no nephrotoxicity or neurotoxicity was observed during the treatment.